Clinical trials: Multiple Chronic Conditions
Elderly Patients, Polypathology
Personalized Digital Remote Monitoring for Elderly Patients
Objective This clinical investigation aims to evaluate whether the EPOCA Remote Monitoring System (RMS) enhances care for elderly patients with multiple chronic conditions and reduces unplanned hospitalizations.
- Conditions
- Elderly Patients, Polypathology, Multiple Chronic Conditions
- Trial name
- EPOCARE (NCT06845917)
- Testing
- Remote Patient Monitoring system
- Volunteers
- 700 people
- Sponsor
- EPOCA U&I
Multiple Chronic Conditions, Decision Making, Shared
Effect of Patient Priorities Care Implementation in Older Veterans With Multiple Chronic Conditions
The investigators will conduct a randomized control trial enrolling 420 older Veterans with multiple chronic conditions receiving primary care at the Michael E.
- Trial name
- PPC (NCT04922320)
- Testing
- Patient Priorities Care, Usual Care
- Where
- 2 sites in United States
- Volunteers
- 437 people
- Sponsor
- VA Office of Research and Development
Chronic Kidney Disease
Multi-disciplinary Participatory Design of a Process to Deliver a CKD Diagnosis in Primary Care
This study will use an adapted education worksheet to support patient-centered chronic kidney disease (CKD) communication, shared decision making, and patient engagement and will test its impact on intermediate patient modifiable…
- Trial name
- EPIK (NCT03084159)
- Testing
- Education worksheet
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- University of Michigan
Peripheral Arterial Disease
Single Arm Study With a Nitinol Self-Expanding Paclitaxel-Eluting Stent to Treat BTK Arteries
The objective of this clinical study is to evaluate the immediate and long-term (up to 12 month) safety and effectiveness of a Nitinol Self-Expanding Paclitaxel-Eluting stent for the treatment of patients with critical limb…
- Trial name
- PES-BTK-70 (NCT01630070)
- Testing
- Self-expandable drug eluting stent
- Where
- 5 sites in Belgium
- Volunteers
- 70 people
- Sponsor
- Flanders Medical Research Program
Depression, Multiple Chronic Conditions
An Approach to "Move a Little & Often" With Health Conditions
People with long term conditions such as diabetes and arthritis, and who also have depression spend a lot of time sedentary during the day. This is because they face many barriers to being active, such as pain and fatigue.
- Trial name
- NCT03537053
- Testing
- A plan to Move a Little and Often
- Where
- 2 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Manchester
Secondary Progressive Multiple Sclerosis
Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)
This is a prospective, randomized, multicenter, dose escalation study to determine subject safety, pharmacokinetic, and pharmacodynamic responses in patients with SPMS
- Trial name
- NCT01181089
- Testing
- Baminercept
- Sponsor
- Biogen
Chronic Subdural Hematoma, Subdural Drain
The Effect of Subdural Drain Placement After Burr Hole Evacuation of Chronic Subdural Haematomas on Recurrence: a Prospective Randomised-controlled Multi-centre Study
This is a prospective randomised-controlled multi-centre trial based in Hong Kong to determine whether temporary subdural drain placement after burr hole evacuation of a chronic subdural haematoma can reduce the risk of…
- Trial name
- NCT01785797
- Testing
- Silicon subdural drain placement after burr hole evacuation of chronic subdural hematoma
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Kwong Wah Hospital
Pruritus
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
The main objective of the study is to assess efficacy and safety of dupilumab given up to 24 weeks in adults with CPUO. This is a master protocol which includes 2 parallel-treatment, double-blind, 2- arm Phase 3 staggered studies…
- Trial name
- NCT05263206
- Testing
- Dupilumab, Fexofenadine (loratadine if not available)
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 284 people
- Sponsor
- Sanofi
IgA Nephropathy, Renal Insufficiency, Chronic
Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?
Global Burden of Diseases ranks chronic kidney disease (CKD) as the 12th leading cause of death, with an estimated 20% increase from 2010 to 2019.
- Conditions
- IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis, IGA Glomerulonephritis
- Trial name
- IA-GRACE-IgANT (NCT06676384)
- Testing
- Oral prednisolone and SoC, Gut-directed budesonide and SoC, Mycophenolate mofetil (MMF) and SoC
- Where
- 12 sites in India
- Volunteers
- 585 people
- Sponsor
- Christian Medical College, Vellore, India
Hepatitis B, Chronic
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Participants and Chronic Hepatitis B Patients
This is a multiple-center, randomized, double-blind, placebo-controlled, single-ascending dose and multiple-ascending dose, adaptive parallel study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of…
- Trial name
- NCT02604355
- Testing
- RO7020322
- Where
- 4 sites in Hong Kong, New Zealand and 1 more
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Pulmonary Disease, Chronic Obstructive
High Dose Trial in COPD
The primary objective of this study was to compare the efficacy and safety of 200 μg and 400 μg of BEA 2180 BR to tiotropium 5 μg and placebo when each was delivered by the Respimat® Inhaler once daily for four weeks in patients…
- Trial name
- NCT00128440
- Testing
- BEA 2180 BR, tiotropium
- Where
- 13 sites in United States
- Volunteers
- 78 people
- Sponsor
- Boehringer Ingelheim
Arterio-Venous Fistula, Kidney Failure, Chronic
VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ
This is a prospective single arm study enrolling patients who are scheduled for creation of a new Brachiocephalic or Radiocephalic AV fistula.
- Conditions
- Arterio-Venous Fistula, Kidney Failure, Chronic, Kidney Diseases, Renal Failure Chronic
- Trial name
- VALUE (NCT03246984)
- Testing
- VasQ
- Where
- 11 sites in France, Germany and 2 more
- Volunteers
- 80 people
- Sponsor
- Laminate Medical Technologies
Chronic Lymphocytic Leukemia
Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy
The purpose of this study is to determine the highest tolerated dose, safety and activity of HCD122 in patients with chronic lymphocytic leukemia who are relapsed after receiving prior treatment.
- Trial name
- NCT00108108
- Testing
- HCD122
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
End Stage Renal Disease
A Multiple-Dose Study of Oral Oseltamivir in Participants on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)
This study is designed to assess the pharmacokinetics (PK) and safety of oseltamivir and its metabolite oseltamivir carboxylate in participants undergoing routine HD and CAPD for end-stage renal disease (ESRD).
- Trial name
- NCT02617784
- Testing
- Oseltamivir
- Where
- New Zealand
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, NMO Spectrum Disorder
National, Multicentric Registry Study on Neuroimmunological Diseases in China
The aim of this study is to establish a real-world clinical neuroimmune disease research cohort, to follow up and observe the prognosis of patients with different subtypes and subgroups, and to provide support for the treatment…
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Myasthenia Gravis
- Trial name
- NIDBase (NCT06443333)
- Testing
- Data collection and follow-up observation, Data collection
- Where
- China
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Leukemia, Leukemia, Myeloid
Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
In this study, the efficacy and safety of two radotinib doses, 300 mg twice daily and 400 mg twice daily, will be compared with imatinib 400 mg once daily in newly diagnosed patients with Philadelphia chromosome-positive (Ph+)…
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Philadelphia Chromosome
- Trial name
- NCT01511289
- Testing
- Imatinib, Radotinib
- Where
- 22 sites in Indonesia, Philippines and 2 more
- Volunteers
- 242 people
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
This randomized phase III trial studies how well graft-vs-host disease (GVHD) prophylaxis works in treating patients with hematologic malignancies undergoing unrelated donor peripheral blood stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT01231412
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate
- Where
- 11 sites in United States, Denmark and 1 more
- Volunteers
- 174 people
- Sponsor
- Fred Hutchinson Cancer Center
Pulmonary Disease, Chronic Obstructive
Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
Direct comparison studies of the tiotropium HandiHaler® 18 µg and Respimat® 5 µg formulations have been limited to 4-week crossover studies.
- Trial name
- NCT01126437
- Testing
- tiotropium 18 mcg, tiotropium 1.25 mcg (2 actuations/day), tiotropium 2.5 mcg (2 actuations/day)
- Where
- 1,191 sites in United States, Argentina and 49 more
- Volunteers
- 17,183 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate, after 1 week of dosing, the efficacy and safety of PT003 compared with its individual components (PT001 and PT005), placebo and two active comparators to demonstrate superiority of the…
- Trial name
- NCT01085045
- Testing
- PT003 MDI, PT005 MDI, Tiotropium bromide 18 μg (Spiriva Handihaler®)
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 118 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Myeloproliferative Disorders, Leukemia
T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Malignant Plasma Cell Neoplasms
- Trial name
- NCT00589602
- Testing
- peripheral blood lymphocyte therapy, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- The Cleveland Clinic